CUSIP: 89422GAA5
Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Debt / NOTE 2.250% 3/0
-
Market price (% of par)
-
86.4%
-
Total 13F principal
-
$257,683,037
-
Principal change
-
+$4,792,295
-
Total reported market value
-
$224,077,029
-
Number of holders
-
25
-
Value change
-
+$11,645,577
-
Number of buys
-
12
-
Number of sells
-
11
Security key
89422GAA5
Report period
Q3 2024
Institutions
25
Top holders
10
Reporting periods
Holder history for CUSIP 89422GAA5
Recent filing periods:
Top shareholders of 89422GAA5 - TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q3 2024
As of 30 Sep 2024,
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by
25 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$257,683,037
in principal (par value) of the bond.
The largest 10 bondholders included
WOLVERINE ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., OAKTREE CAPITAL MANAGEMENT LP, Linden Advisors LP, Graham Capital Management, L.P., SILVERBACK ASSET MANAGEMENT LLC, CAPSTONE INVESTMENT ADVISORS, LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, AQR Arbitrage LLC, and Point72 Asset Management, L.P..
This page lists
25
institutional bondholders reporting positions
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
Compare Q3 2024 vs Q2 2024 Across Filers
| Investor |
Q2 2024 Shares |
Q3 2024 Shares |
Share Diff |
Share Chg % |
Q2 2024 Value $ |
Q3 2024 Value $ |
Value Diff $ |
Value Chg % |
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.